Page 965 - Read Online

Brodosi et al. Hepatoma Res 2020;6:82 I http://dx.doi.org/10.20517/2394-5079.2020.88 Page 9 of 11

2007;356:2457-71.
27. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a
meta-analysis of randomized trials. JAMA 2007;298:1180-8.
28. Musso G, Cassader M, Paschetta E, Gambino R. Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new
challenges. Hepatology 2017;65:1058-61.
29. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with
chronic liver disease. Liver Int 2010;30:750-8.
30. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic
review and meta-analysis. J Clin Endocrinol Metab 2012;97:2347-53.
31. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic
review and meta-analysis. Am J Gastroenterol 2013;108:881-91; quiz 892.
32. Yu H, Zhong X, Gao P, et al. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne) 2019;10:617.
33. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of
patients with diabetes. Hepatology 2014;60:2008-16.
34. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18:S10-5.
35. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18:S10-5.
36. Belfort R, Harrison SA, Brown K, Darland C, Finch J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic
steatohepatitis. N Engl J Med 2006;355:2297-307.
37. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med
2006;355:2297-307.
38. Chalasani NP, Sanyal AJ, Kowdley KV, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with
non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;30:88-96.
39. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology
2004;39:188-96.
40. Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J
Med 2010;362:1675-85.
41. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-
analysis. JAMA Intern Med 2017;177:633-40.
42. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in
the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet
2005;366:1279-89.
43. Kernan WN, Viscoli CM, Furie KL, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl
J Med 2016;374:1321-31.
44. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in
type 2 diabetes mellitus. Hepatology 2012;55:1462-72.
45. Bril F, Lomonaco R, Kalavalapalli S, Lai J, Cusi K. 223-OR: Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis
(NASH) is associated with disease recurrence. Diabetes 2019;68:223-OR.
46. Motola D, Piccinni C, Biagi C, et al. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a
disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 2012;35:315-23.
47. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2
diabetes. Lancet 2006;368:1696-705.
48. Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review
and meta-analysis. J Gastroenterol Hepatol 2016;31:23-31.
49. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic
steatohepatitis. Acta Gastroenterol Belg 2012;75:240-4.
50. Kanazawa I, Tanaka K, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit
2014;20:1662-7.
51. Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic
steatohepatitis patients: a 1-year randomized control trial. Hepat Med 2018;10:23-31.
52. Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol
2016;65:369-76.
53. Smits MM, Tonneijck L, Muskiet MH, et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a
randomised placebo-controlled trial. Diabetologia 2016;59:2588-93.
54. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides 2018;100:61-7.
55. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver
enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37:234-42.
56. Eguchi Y, Kitajima Y, Hyogo H, et al; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic
steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015;45:269-78.
57. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a
multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387:679-90.